HOW AND WHERE TO BUY INSULIN GLARGINE (LANTUS) 100 IU / ML INJECTIONS ONLINE:
from $82.80 per Lantus pen
5% discount coupon: dmeds5
from $418.00 per Lantus box
5% discount coupon: dmeds5
from $450.00 per Lantus pack
5% discount coupon: MSD5
LANTUS (INSULIN GLARGINE): ADVERSE REACTIONS / SIDE EFFECTS
The following adverse reactions are discussed elsewhere:
Hypersensitivity and allergic reactions
Clinical trial experience
Because clinical trials are conducted under widely varying designs, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practice.
The frequencies of treatment-emergent adverse events during Lantus Insulin clinical trials in patients with type 1 diabetes mellitus and type 2 diabetes mellitus:
Treatment - emergent adverse events in pooled clinical trials up to 28 weeks duration in adults with type 1 diabetes (adverse events with frequency >= 5%): upper respiratory tract infection, body system not specified infection, accidental injury, headache.
Treatment - emergent adverse events in pooled clinical trials up to 1 year duration in adults with type 2 diabetes (adverse events with frequency >= 5%): upper respiratory tract infection, body system not specified infection, retinal vascular disorder.
Treatment - emergent adverse events in a 5-year trial of adults with type 2 diabetes (adverse events with frequency >= 10%): upper respiratory tract infection, edema peripheral, hypertension, influenza, sinusitis, cataract, bronchitis, arthralgia, pain in extremity, back pain, cough, urinary tract infection, diarrhea, depression, headache.
Treatment - emergent adverse events in a 28-week clinical trial of children and adolescents with type 1 diabetes (adverse events with frequency >= 5%): body system not specified infection, upper respiratory tract infection, pharyngitis, rhinitis.
Hypoglycemia is the most commonly observed adverse reaction in patients using insulin, including Lantus (Insulin Glargine). Severe symptomatic hypoglycemia was defined as an event with symptoms consistent with hypoglycemia requiring the assistance of another person and associated with either a blood glucose below 50 mg / dl ( <= 56 mg / dl in the 5-year trial) or prompt recovery after oral carbohydrate, intravenous glucose or glucagon administration. The rates of severe symptomatic hypoglycemia in the Insulin Glargine (Lantus) clinical trials were comparable for all treatment regimens. In the pediatric phase 3 clinical trial, children and adolescents with type 1 diabetes had a higher incidence of severe symptomatic hypoglycemia in the two treatment groups compared to the adult trials with type 1 diabetes.
Retinopathy was evaluated in the Lantus (Insulin Glargine) injections clinical studies by analysis of reported retinal adverse events and fundus photography. The numbers of retinal adverse events reported for Lantus insulin injections and NPH insulin treatment groups were similar for patients with type 1 and type 2 diabetes. Lantus insulin injections was compared to NPH insulin in a 5-year randomized clinical trial that evaluated the progression of retinopathy as assessed with fundus photography using a grading protocol derived from the Early Treatment Diabetic Retinopathy Scale (ETDRS). Patients had type 2 diabetes (mean age 55 yrs) with no (86%) or mild (14%) retinopathy at baseline. Mean baseline HbA1c was 8.4%. The primary outcome was progression by 3 or more steps on the ETDRS scale at study endpoint. Patients with pre-specified post-baseline eye procedures (pan-retinal photocoagulation for proliferative or severe nonproliferative diabetic retinopathy, local photocoagulation for new vessels, and vitrectomy for diabetic retinopathy) were also considered as 3-step progressors regardless of actual change in ETDRS score from baseline. Retinopathy graders were blinded to treatment group assignment.
Insulin initiation and intensification of glucose control
Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy,
and acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk of diabetic retinopathy and neuropathy.
Long-term use of insulin, including Lantus (Insulin Glargine) injections 100 IU / ml, can cause lipodystrophy at the site of repeated insulin injections. Lipodystrophy includes lipohypertrophy (thickening of adipose tissue) and lipoatrophy (thinning of adipose tissue), and may affect insulin absorption. Rotate insulin injection or infusion sites within the same region to reduce the risk of lipodystrophy.
Weight gain can occur with insulin therapy, including Insulin Glargine (Lantus) injections, and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.
Insulin, including Lantus injections, may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.
Allergic Reactions Local Allergy
As with any insulin therapy, patients taking Insulin Glargine injections may experience injection site reactions, including redness, pain, itching, urticaria, edema, and inflammation. In clinical studies in adult patients, there was a higher incidence of treatment-emergent injection site pain in Lantus-treated patients (2.7%) compared to NPH insulin-treated patients (0.7%). The reports of pain at the injection site did not result in discontinuation of therapy.
Rotation of the injection site within a given area from one injection to the next may help to reduce or prevent these reactions. In some instances, these reactions may be related to factors other than insulin, such as irritants in a skin cleansing agent or poor injection technique. Most minor reactions to insulin usually resolve in a few days to a few weeks.
Severe, life-threatening, generalized allergy, including anaphylaxis, generalized skin reactions, angioedema, bronchospasm, hypotension, and shock may occur with any insulin, including Lantus and may be life threatening.
All insulin products can elicit the formation of insulin antibodies. The presence of such insulin antibodies may increase or decrease the efficacy of insulin and may require adjustment of the insulin dose. In phase 3 clinical trials of Lantus Insulin, increases in titers of antibodies to insulin were observed in NPH insulin and insulin glargine treatment groups with similar incidences.
The following adverse reactions have been identified during post-approval use of Insulin Glargine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure.
Medication errors have been reported in which other insulins, particularly short-acting insulins, have been accidentally administered instead of Lantus (Insulin Glargine). To avoid medication errors between Insulin Glargine (Lantus) and other insulins, patients should be instructed to always verify the insulin label before each injection.
Buy Lantus (Insulin Glargine) Online
Lantus prescribing information
Copyright © Buy Insulin Glargine (Lantus) Online